**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Santiago Decotto, Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina.

**Main Body of the Abstract**
Background: Cardiac transplantation was not considered an option in amyloidosis patients in the past because it was considered a systemic disease with poor outcomes. Nowadays it is no longer a contraindication but still represents a medical challenge.
Objective: To describe the clinical and imaging characteristics of patients who underwent heart transplantation due to amyloidosis, in a healthcare center in Argentina.
Method: Descriptive case series of consecutive heart transplantation patients with amyloidosis. We included all patients with a diagnosis of amyloidosis cardiomyopathy who received a heart transplant in the period from November 2008 to February 2021.
Results: A total of 16 patients were included. The mean age was 60 (± 10) years, 81% (n = 13) were male. According to the type of amyloidosis, 12 patients were transplanted for AL amyloidosis and 4 for ATTR amyloidosis (features in TABLE). The most frequent clinical presentations were left overload (50%) and cardiogenic shock (32%). The mean left ventricle ejection fraction prior to transplantation was 43 (± 16%), 14 of the 16 patients had right ventricular dysfunction. The most common finding on cardiac magnetic resonance was the diffuse subendocardial late gadolinium enhancement pattern. The heart transplantation gave 6 patients the chance to receive a bone marrow transplantation afterward.
Conclusions: Heart transplantation has become an option for patients with heart failure due to AL and ATTR amyloidosis. In patients with AL amyloidosis, it might even allow bone marrow transplantation in a second stage.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Santiago Decotto, Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina.

**Main Body of the Abstract**
**Background**: Cardiac transplantation was not considered an option in amyloidosis patients in the past because it was considered a systemic disease with poor outcomes. Nowadays it is no longer a contraindication but still represents a medical challenge.
**Objective**: To describe the clinical and imaging characteristics of patients who underwent heart transplantation due to amyloidosis, in a healthcare center in Argentina.
**Method**: Descriptive case series of consecutive heart transplantation patients with amyloidosis. We included all patients with a diagnosis of amyloidosis cardiomyopathy who received a heart transplant in the period from November 2008 to February 2021.
**Results**: A total of 16 patients were included. The mean age was 60 (± 10) years, 81% (n = 13) were male. According to the type of amyloidosis, 12 patients were transplanted for AL amyloidosis and 4 for ATTR amyloidosis (features in TABLE). The most frequent clinical presentations were left overload (50%) and cardiogenic shock (32%). The mean left ventricle ejection fraction prior to transplantation was 43 (± 16%), 14 of the 16 patients had right ventricular dysfunction. The most common finding on cardiac magnetic resonance was the diffuse subendocardial late gadolinium enhancement pattern. The heart transplantation gave 6 patients the chance to receive a bone marrow transplantation afterward.
**Conclusions**: Heart transplantation has become an option for patients with heart failure due to AL and ATTR amyloidosis. In patients with AL amyloidosis, it might even allow bone marrow transplantation in a second stage.



Heart transplantation in amyloidosis in a developing country. Clinical and imaging manifestations. PB151 (#415)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.